But now two new treatments for tardive dyskinesia are available. Valbenazine, developed by Neurocine Biosciences, was approved in April 2017 and is being marketed under the name Ingrezza. Deutetrabenazine, brought to market by Teva, was approved a few months later and is being sold under the name Austedo. Like tetrabenazine, they are in the VMAT2 family. The mechanism of action is unclear, but it’s thought to be mediated through the reversible inhibition of VMAT2, which regulates monoamine uptake from the cytoplasm to the synaptic vesicle.
9 Likes
Sure the first one costs an ungodly amount of money.
4 Likes
If my TD ever got awful, I was going to have to switch meds. But I don’t want to switch meds.
Jayster
3 Likes
so it costs $90 k a day for a TD pill? woooooooooooooooo
2 Likes
“But let’s consider the prices. ICER pegged the wholesale acquisition cost (WAC) of a daily 80-mg dose of Ingrezza at $75,789 and the WAC for a daily 36-mg dose of Austedo at $90,071.”
I’m pretty sure that has got to be the annual cost of a daily dose.
Still ridiculously expensive.